{"schema_version":"secwatch.filing_event.v1","accession":"0001619856-26-000012","form_type":"8-K","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2026-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.657669+00:00","generated_at":"2026-05-15T08:10:02.603101+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Caribou gets RMAT designation from FDA for CB-011 in relapsed/refractory multiple myeloma","bullets":["FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation for CB-011 allogeneic anti-BCMA CAR-T.","RMAT based on CaMMouflage phase 1 dose escalation data: 92% ORR, 75% ≥CR, 91% MRD negativity in 12 BCMA-naïve patients at RDE.","No graft-versus-host disease or certain neurotoxicities observed; manageable safety profile reported.","Dose expansion enrollment ongoing for both BCMA-naïve and BCMA-exposed cohorts; additional data expected in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001619856-26-000012","json":"https://secwatch.observer/filing/0001619856-26-000012.json","markdown":"https://secwatch.observer/filing/0001619856-26-000012.md","text":"https://secwatch.observer/filing/0001619856-26-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000161985626000012/0001619856-26-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000161985626000012/crbu-20260331.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:10:02.603101+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}